About
Technology
Issues
FAQ
Links
Official Page
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.